Lupus (SLE)

Clinical Trials for Lupus

Clinical Trials for Lupus

General purpose: Research may investigate a variety of potential topics, including: potential causes of lupus, factors that may prevent the onset of lupus, genetic mutations associated with an increased risk of developing lupus.

The role of the body’s immune system in the development of lupus, environmental factors that may cause lupus or exacerbate its symptoms. The gender differences associated with the risk and severity of lupus, new treatments, and ways to prevent lupus from attacking various body systems and organs (such as the central nervous system, kidneys, and skin).

Clinical Trials for Lupus Continued … (Click to Open)

Join Clinical Trials for Systemic Lupus Erythematosus (SLE)

SLE Clinical Trials

What do typical clinical trials for Lupus involve?

Clinical trials will vary widely in the information they collect, as well as the tests and procedures they use. All of these factors will depend on individual study designs, which will differ greatly between trials. However, below is a list of common procedures and data that are frequently collected during a trial for lupus:

  • Detailed personal information related to prior environmental, chemical, and biologic exposures.
  • Prior history of various diseases, such as rheumatoid arthritis, chronic fatigue syndrome, fibromyalgia, and others.
  • Blood tests to measure:
    • Antibodies, including antinuclear antibodies (ANA) panel, antithyroglobulin antibody, antithyroid microsomal antibody, complement component antibodies C3 and C4, cryoglobulins, erythrocyte sedimentation rate (ESR, or “sed rate”)
    • Complete blood count (CBC)
    • Rheumatoid factor
  • Chest x-ray
  • Kidney biopsy
  • Urine tests
  • Kidney function tests
  • Liver function tests

Examples of Lupus-related research topics:

Improved understanding of how and why lupus develops by comparing the personal histories and exposures of patients with lupus. These may include:

  • Studies to assess potential genetic influences.
  • Studies to assess environmental influences (chemical, occupational).
  • Studies to evaluate biologic factors (bacterial or viral infections; individual immune system characteristics).
  • Studies to determine new and effective medications to treat lupus.
  • Studies to observe the long-term effects of lupus on the body and mind, using imaging tests, mental health evaluations, and observation.

Suggested search terms related to Systemic Lupus Erythematosus:

“systemic lupus erythematosus treatment,” “systemic lupus erythematosus prevention,” “systemic lupus erythematosus diagnosis,” “pediatric systemic lupus erythematosus,” “systemic lupus erythematosus organ damage,” and “systemic lupus erythematosus autoimmune.”



A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: Placebo;   Drug: M2951;   Drug: M2951;   Drug: M2951
Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA
Recruiting - verified March 2017


Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: Belimumab
Sponsor:   GlaxoSmithKline
Recruiting - verified May 2017


A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus (SLE)
Interventions:   Drug: Placebo;   Drug: Dapirolizumab pegol (DZP)
Sponsor:   UCB Biopharma S.P.R.L.
Recruiting - verified May 2017


Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Interventions:   Other: Drug free;   Drug: HCQ;   Drug: GC+HCQ
Sponsors:   Peking Union Medical College Hospital;   Xiangya Hospital of Central South University;   Shengjing Hospital;   People's Hospital of Xinjiang Uygur Autonomous Region;   Anhui Provincial Hospital
Recruiting - verified March 2017


Walk With Ease Program For Patients With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Other: "Walk With Ease"
Sponsors:   University of North Carolina, Chapel Hill;   North Carolina Translational and Clinical Sciences Institute
Recruiting - verified April 2017


Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: prednisone discontinuation
Sponsor:   Groupe Hospitalier Pitie-Salpetriere
Recruiting - verified August 2016


Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: ACT-334441;   Drug: Placebo
Sponsor:   Actelion
Completed - verified March 2017


Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus


Condition:   Active Systemic Lupus Erythematosus
Interventions:   Biological: Anifrolumab;   Drug: Placebo
Sponsors:   AstraZeneca;   PRA Health Sciences
Recruiting - verified May 2017


Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus


Condition:   Active Systemic Lupus Erythematosus
Interventions:   Biological: Anifrolumab;   Drug: Placebo
Sponsors:   AstraZeneca;   PRA Health Sciences
Recruiting - verified May 2017


Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus


Condition:   Systemic Lupus Erythematosus
Intervention:   Other: therapeutic education
Sponsors:   University Hospital, Lille;   Région Nord-Pas de Calais, France
Recruiting - verified February 2017


Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: MT-1303 Low dose;   Drug: MT-1303 High dose
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Active, not recruiting - verified January 2017


A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: CC-220;   Drug: CC-220;   Drug: CC-220;   Drug: CC-220;   Drug: Placebo
Sponsor:   Celgene
Active, not recruiting - verified May 2017


Nelfinavir in Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: Nelfinavir
Sponsors:   Northwell Health;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2017


Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry


Condition:   Systemic Lupus Erythematosus
Interventions:   Biological: BENLYSTA;   Other: SLE treatment
Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
Recruiting - verified January 2017


Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)


Condition:   Systemic Lupus Erythematosus
Interventions:   Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
Recruiting - verified April 2017


International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:  
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed - verified July 2016


A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Interventions:   Biological: Anifrolumab 300 mg;   Biological: Anifrolumab 1000 mg;   Other: Placebo
Sponsor:   MedImmune LLC
Completed - verified August 2016


A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Interventions:   Biological: Sifalimumab 200 mg;   Biological: Sifalimumab 600 mg;   Biological: Sifalimumab 1,200 mg;   Other: Placebo
Sponsor:   MedImmune LLC
Completed - verified July 2016


Systemic Lupus Erythematosus in Gullah Health


Condition:   Systemic Lupus Erythematosus
Intervention:  
Sponsors:   Medical University of South Carolina;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified August 2016


Aspirin Resistance in Systemic Lupus Erythematosus (SLE)


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: aspirin and meloxicam
Sponsors:   Vanderbilt University;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified October 2016


A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
Sponsors:   Human Genome Sciences Inc.;   GlaxoSmithKline
Completed - verified October 2016


A Study of Belimumab in Subjects With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
Sponsors:   Human Genome Sciences Inc.;   GlaxoSmithKline
Completed - verified December 2016


Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Biological: Hematopoietic stem cell transplantation
Sponsor:   Northwestern University
Active, not recruiting - verified January 2017


Monoclonal Antibody Treatment for Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: MRA 003 US
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed - verified April 3, 2017


Study of Systemic Lupus Erythematosus


Condition:   Systemic Lupus Erythematosus
Intervention:  
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 5, 2017

Refine Your Search Advanced Search